The HDAC6 inhibitor nexturastat A improves the efficacy of anti-PD-1 antibody by decreasing the number of pro-tumorigenic M2 macrophages (TAMs) while increasing the number of tumor infiltrating NK cells and CD8+ T cells (Knox et al., 2019, Figure 5D). Here, HDAC6 is linked to neoplasm.